NEW YORK, February 10, 2017 /PRNewswire/ --
For today, Stock-Callers.com is focused on the Medical Instruments and Supplies industry which primarily researches, develops
and produces non-electronic medical, surgical, dental, and veterinary instruments and apparatus. Equities under evaluation this
morning are: Waters Corp. (NYSE: WAT), Insulet Corp. (NASDAQ: PODD), Integra LifeSciences Holdings Corp. (NASDAQ: IART), and The
Cooper Cos. Inc. (NYSE: COO). Learn more about these stocks by downloading their free report at:
http://stock-callers.com/registration
Waters
Massachusetts-based Waters Corp.'s stock finished Thursday's session 0.74% higher at
$148.67 with a total trading volume of 334,622 shares. The Company's shares have advanced 8.08% in
the past month, 5.33% in the previous three months, and 10.63% since the start of this year. The stock is trading 6.69% and 2.69%
above its 50-day and 200-day moving averages, respectively. Additionally, shares of Waters, which operates as an analytical
instrument manufacturer in the US and internationally, have a Relative Strength Index (RSI) of 64.74.
On January 18th, 2017, research firm Deutsche Bank initiated a 'Buy' rating on the
Company's stock, with a target price of $160 per share.
On January 24th, 2017, Waters reported Q4 2016 sales of $629
million, a 7% increase versus sales of $587 million in Q4 2015. On a GAAP basis, the
Company's earnings per diluted share for Q4 2016 were up 17% to $2.15 compared to $1.83 for Q4 2015. The free research report on WAT is available at:
http://stock-callers.com/registration/?symbol=WAT
Insulet
On Thursday, shares in Massachusetts headquartered Insulet Corp. recorded a trading volume of
278,903 shares. The stock ended the session 0.17% higher at $42.30. The Company's shares have
advanced 2.67% in the last one month, 19.56% over the previous three months, and 12.26% on an YTD basis. The stock is trading
8.40% above its 50-day moving average and 14.91% above its 200-day moving average. Moreover, shares of Insulet, which develops,
manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the US, have an RSI of 58.19.
On January 23rd, 2017, Insulet announced plans to release its Q4 and full year 2016
financial results on February 27th, 2017, after the close of the financial markets. In
connection with the release, the Company's management will host a conference call on the same day at 4:30
p.m. ET. The complimentary report on PODD can be downloaded at:
http://stock-callers.com/registration/?symbol=PODD
Integra LifeSciences
Shares in Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp. closed the
day 1.50% higher at $43.18. The stock recorded a trading volume of 404,923 shares. The Company's
shares have gained 7.71% in the previous three months and 0.66% on an YTD basis. The stock is trading 3.46% and 6.83% above its
50-day and 200-day moving averages, respectively. Additionally, shares of Integra LifeSciences Holdings, which develops,
manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction,
orthopedics, and general surgery, have an RSI of 61.57.
On January 13th, 2017, research firm RBC Capital Markets reiterated its 'Sector
Perform' rating on the Company's stock with a decrease of the target price from $85 a share to
$46 a share.
On January 25th, 2017, Integra announced that its wholly-owned subsidiary, Integra
Derma, Inc., is commencing a cash tender offer to purchase all outstanding common and preferred shares of Derma Sciences, Inc.
(DSI) at an offer price of $7.00 per share for DSI's common stock, $32.00 per share for DSI's Series A Convertible Preferred Stock and $48.00 per
share for DSI's Series B Convertible Preferred Stock. The tender offer is being made in connection with the Agreement and Plan of
Merger, dated January 10th, 2017, among Integra, Integra Derma and DSI. The tender offer
will expire at 12:00 midnight, ET, on February 22nd, 2017. Visit us today and download
our complete research report on IART for free at:
http://stock-callers.com/registration/?symbol=IART
Cooper
At the close of trading on Thursday, shares in Pleasanton, California headquartered The
Cooper Cos. Inc. finished 0.82% higher at $190.50. The stock recorded a trading volume of 262,093
shares. The Company's shares have advanced 4.80% in the last one month, 4.17% over the previous three months, and 8.92% since the
start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.74% and 8.98%, respectively.
Furthermore, shares of Cooper Cos., which develops, manufactures, and markets a range of contact lenses, including spherical
lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual
defects, such as astigmatism and presbyopia, have an RSI of 74.31.
On February 01st, 2017, Cooper announced that it will release Q1 FY17 financial
results on March 02nd, 2017, at 4:15 PM ET. The Company
will host a conference call at 5:00 PM ET on the same day to discuss the results and current
corporate developments. Get free access to your technical report on COO at:
http://stock-callers.com/registration/?symbol=COO
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA